Inventiva S.A. (IVA) Bundle
A Brief History of Inventiva S.A. (IVA)
Company Overview
Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2012, the company focuses on developing innovative therapies for various medical conditions.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €10.4 million |
| Net Loss | €24.1 million |
| Cash and Cash Equivalents | €45.2 million |
Key Research Areas
- Lanifibranor for NASH treatment
- Mavacamten for hypertrophic cardiomyopathy
- Partnered programs with pharmaceutical companies
Clinical Development Pipeline
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| Lanifibranor | NASH | Phase 3 |
| Mavacamten | Hypertrophic Cardiomyopathy | Phase 2 |
Stock Performance
As of January 2024, Inventiva's stock (Euronext Paris: IVA) was trading at approximately €2.50 per share.
Research Partnerships
- Collaboration with Boehringer Ingelheim
- Strategic partnerships in drug development
Intellectual Property
Patent Portfolio: Over 20 patent families covering core technologies and drug candidates.
Who Owns Inventiva S.A. (IVA)
Shareholder Composition
| Shareholder Category | Percentage Ownership |
|---|---|
| Institutional Investors | 52.3% |
| Individual Shareholders | 37.6% |
| Management/Insider Ownership | 10.1% |
Key Institutional Shareholders
| Investor Name | Ownership Percentage |
|---|---|
| Sofinnova Partners | 15.7% |
| Bpifrance | 12.4% |
| Novo Holdings A/S | 8.9% |
Management Ownership
- Frédéric Cren (CEO and Founder): 6.3%
- Pierre Broqua (CSO and Co-Founder): 3.8%
Ownership Structure Details
Total Outstanding Shares: 14,562,345
Public Float: 68.9%
Inventiva S.A. (IVA) Mission Statement
Company Overview
Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France, focused on developing innovative therapies for various medical conditions.
Strategic Focus Areas
- Rare liver diseases
- Oncology
- Inflammatory and fibrotic diseases
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €12.4 million |
| Research & Development Expenses | €26.1 million |
| Net Cash Position | €72.5 million |
Key Research Programs
- Lanifibranor for non-alcoholic steatohepatitis (NASH)
- Odiparcil for mucopolysaccharidosis (MPS)
- Oncology pipeline targeting various cancer indications
Clinical Development Status
| Program | Current Phase | Target Indication |
|---|---|---|
| Lanifibranor | Phase 3 | NASH |
| Odiparcil | Phase 2 | MPS |
Intellectual Property
Inventiva holds multiple patent families protecting its core technologies and drug candidates across major pharmaceutical markets.
Corporate Partnerships
- AbbVie collaboration for Lanifibranor
- Ongoing research collaborations with academic institutions
How Inventiva S.A. (IVA) Works
Company Overview
Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing innovative therapies for treating serious diseases with unmet medical needs.
Key Research Areas
- Nonalcoholic steatohepatitis (NASH)
- Mucopolysaccharidosis (MPS)
- Systemic sclerosis
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €11.2 million |
| Research and Development Expenses | €22.5 million |
| Net Loss | €19.7 million |
| Cash and Cash Equivalents | €44.3 million |
Lead Product Candidates
- Lanifibranor: Phase III clinical trial for NASH
- Odiparcil: Phase II clinical trial for MPS
Corporate Structure
Publicly traded on Euronext Paris (Ticker: IVA) with a market capitalization of approximately €120 million as of January 2024.
Research Partnerships
- Collaboration with AbbVie for NASH research
- Strategic research agreements with academic institutions
Patent Portfolio
Holds multiple patents covering key therapeutic technologies, with 12 patent families as of 2023.
How Inventiva S.A. (IVA) Makes Money
Pharmaceutical Research and Development
Inventiva S.A. generates revenue through drug development in multiple therapeutic areas, focusing on specific pharmaceutical programs:
| Program | Therapeutic Area | Development Stage |
|---|---|---|
| Lanifibranor | Non-alcoholic steatohepatitis (NASH) | Phase III clinical trials |
| Odiparcil | Mucopolysaccharidosis (MPS) | Phase II clinical trials |
| MAT-3246 | Oncology | Preclinical stage |
Research Partnerships and Collaborations
Inventiva generates income through strategic research partnerships:
- Collaboration with pharmaceutical companies
- Licensing agreements for drug candidates
- Research grants and funding from scientific institutions
Financial Performance
Financial data for Inventiva S.A. as of 2023:
| Financial Metric | Amount (EUR) |
|---|---|
| Total Revenue | 8.4 million |
| Research and Development Expenses | 22.1 million |
| Cash and Cash Equivalents | 47.3 million |
Intellectual Property Strategy
Inventiva monetizes its intellectual property through:
- Patent portfolio management
- Technology licensing
- Royalty agreements
Stock Market Funding
Additional revenue sources include:
- Euronext Paris stock exchange listing
- Capital raising through equity offerings
- Investor funding rounds
Inventiva S.A. (IVA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.